| Company Name | Exchange | Ticker | Last Price | Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Colabor Group Inc | TSX | GCL | 3.79 | 6 | Upgrade to buy from hold | Keith E Howlett | Desjardins Securities | 4.50 | 18.7% |
| Input Capital Corp | TSXV | INP | 2.20 | 8 | Upgrade to buy from market perform | Marc Robinson | Cormark Securities Inc. | 2.80 | 27.3% |
| Torstar Corp | TSX | TS/B | 8.15 | 7 | Upgrade to buy from hold | Aravinda Galappatthige | Canaccord Genuity Corp | 8.65 | 6.1% |
| Birchcliff Energy Ltd | TSX | BIR | 12.81 | 11 | Initiate with buy | Dan Tsubouchi | Haywood Securities Inc. | 18.00 | 40.5% |
| New Zealand Energy Corp | TSXV | NZ | 0.15 | 6 | Downgrade to sell from neutral | David Dudlyke | Dundee Securities Corp | 0.10 | -31.0% |
Desjardins Securities upgraded Colabor Group Inc (TSX: GCL), which distributes and markets food and food-related products in Canada, to buy from hold with a price target of C$4.50, an upside of 18.7% from current levels.
Input Capital Corp (TSXV: INP), an agricultural commodity streaming company focused on serving the domestic market for canola production was upgraded at Cormark Securities Inc., to buy from market perform with a price target of C$2.80, an upside of 27.3% from current levels.
Canaccord Genuity Corp upgraded Torstar Corp (TSX: TS/B), which distributes and markets food and food-related products in Canada, to buy from hold with a price target of C$8.65, an upside of 6.1% from current levels.
Haywood Securities Inc. initiated coverage on Birchcliff Energy Ltd (TSX: BIR), a Canada-based media and book publishing company, with buy assigning a 12-month price target of C$18.00, an upside of 40.5% from current levels.
New Zealand Energy Corp (TSXV: NZ), focused on the production and exploration of oil and natural gas prospects in New Zealand, was downgraded at Dundee Securities Corp to sell from neutral, reducing the price target to C$0.10 from C$0.20, a downside of 31.0% from current levels.
| Company Name | Exchange | Ticker | Last Price |
Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Mercer International Inc | NASDAQ | MERC | 8.97 | 7 | Upgrade to outperform from market perform | Daryl Swetlishoff | Raymond James | 10.50 | 17.1% |
| AVANIR Pharmaceuticals Inc | NASDAQ | AVNR | 4.63 | 9 | Upgrade to buy from neutral | Mario V Corso | Mizuho Securities USA Inc | 10.00 | 116.0% |
| Constant Contact Inc | NASDAQ | CTCT | 29.07 | 12 | Upgrade to outperform from neutral | Steven M Ashley | Robert W. Baird & Co | 33.00 | 13.5% |
| La Quinta Holdings Inc | NYSE | LQ | 16.70 | 6 | Initiate with neutral | Joseph R Greff | JPMorgan | 19.00 | 13.8% |
| Endocyte Inc | NASDAQ | ECYT | 6.62 | 10 | Downgrade to neutral from overweight | Edward A Tenthoff | Piper Jaffray | 13.50 | 103.9% |
Raymond James upgraded Mercer International Inc (NASDAQ: MERC), a producer of market northern bleached softwood kraft (NBSK) pulp, to outperform from market perform, raising the price target to $10.50 from $9.50, an upside of 17.1% from current levels.
AVANIR Pharmaceuticals Inc (NASDAQ: AVNR), a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders, was upgraded at Mizuho Securities USA Inc, to buy from neutral, raising the price target to $10.00 from $5.00, an upside of 116.0% from current levels.
Robert W. Baird & Co upgraded Constant Contact Inc (NASDAQ: CTCT), a producer of market northern bleached softwood kraft (NBSK) pulp, to outperform from neutral with a price target of $33.00, an upside of 13.5% from current levels.
JPMorgan initiated coverage on La Quinta Holdings Inc (NYSE: LQ), a provider of on-demand engagement marketing tools that are designed for small organizations, including small businesses, associations and non-profits, with neutral assigning a 12-month price target of $19.00, an upside of 13.8% from current levels.
Endocyte Inc (NASDAQ: ECYT), a biopharmaceutical company engaged in developing therapies for the treatment of cancer and inflammatory diseases, was downgraded at Piper Jaffray to neutral from overweight, reducing the price target to $13.50 from $34.50, an upside of 103.9% from current levels.
